Organisation paid for research Program year 2025 Source: CMS Open Payments

St Clair Nephrology-Roseville

Neither a doctor nor a teaching hospital

Research payments

$432,884

23 payments

Through program year 2025, St Clair Nephrology-Roseville is reported as receiving $432,884 in research payments, across 23 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$334,413	14
2024	Research	$22,108	4
2023	Research	$22,991	2
2022	Research	$53,372	3

Breakdown

Who paid Research payments · program years 2022–2025

Boehringer Ingelheim International GmbH $219,930 15 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $204,676 5 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $8,278 3 payments

Studies the money was for Research payments · program years 2022–2025

A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease $334,413 14 payments
Empa Kidney $68,091 3 payments
Empa-Kidney $12,400 1 payment
Phase III Renal Outcomes $9,000 1 payment
PoCP study in FSGS $8,980 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.